1-2 of 2
Jason E. Hill
Close
Sort by
Journal Articles

Molecular profile of FLT3 -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2144–2155.
https://doi.org/10.1182/bloodadvances.2021006489
Published: 2022
Includes: Supplemental data
Journal Articles

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Clinical Trials & Observations
Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2020) 4 (3): 514–524.
https://doi.org/10.1182/bloodadvances.2019000919
Published: 2020
Includes: Supplemental data